MedTrace Logo

Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients

NCT06570811 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-26

No results posted yet for this study

Summary

investigating the potential effect of Coenzyme Q10 in ameliorating and preventing the development of paclitaxel chemotherapeutic toxicity in breast cancer patients

Conditions

Interventions

DRUG

Placebo

Placebo tablets is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.

DRUG

Coenzyme Q10 200mg twice daily

400 mg daily (200mg twice daily) of Coenzyme Q10 (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.

Sponsors & Collaborators

  • Damanhour University

    lead OTHER

Principal Investigators

  • Amira B Kassem, PhD · Ass.professor in clinical pharmacy ,Faculty of pharmacy Damanhour university

  • Noha Ahmed El Bassiouny, PhD · Ass.professor in clinical pharmacy ,Faculty of pharmacy Damanhour university

  • Ahmed Ashour, PhD · Lecturer in oncology , Faculty of mediciné Alexandria University

  • Yasser Abdelkader · Head of oncology department, Damanhour Oncology Center

  • Gehad Hassoub, Bachelor · Teaching assistant in clinical pharmacy, faculty of pharmacy, Damanhour university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2025-03-10
Completion
2025-03-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06570811 on ClinicalTrials.gov